A detailed history of Gsa Capital Partners LLP transactions in Replimune Group, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 20,254 shares of REPL stock, worth $253,175. This represents 0.02% of its overall portfolio holdings.

Number of Shares
20,254
Holding current value
$253,175
% of portfolio
0.02%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$8.09 - $11.23 $163,854 - $227,452
20,254 New
20,254 $222,000
Q1 2023

May 12, 2023

BUY
$17.48 - $29.09 $413,262 - $687,745
23,642 New
23,642 $417,000
Q2 2022

Aug 09, 2022

SELL
$13.32 - $19.98 $368,884 - $553,326
-27,694 Reduced 31.79%
59,430 $1.04 Million
Q1 2022

May 11, 2022

BUY
$15.24 - $29.75 $1.33 Million - $2.59 Million
87,124 New
87,124 $1.48 Million
Q2 2021

Aug 05, 2021

SELL
$28.5 - $39.37 $210,016 - $290,117
-7,369 Closed
0 $0
Q1 2021

May 10, 2021

BUY
$30.22 - $45.57 $222,691 - $335,805
7,369 New
7,369 $225,000

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $616M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.